SPOT Vision Screening
Accuracy of Welch Allyn Spot™ Vision Screener to Detect Amblyogenic Factors in Developmentally Delayed Children
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Kyle Phillips
- Phone Number: 720-777-0524
- Email: kyle.phillips@childrenscolorado.org
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045-7106
- Recruiting
- Children's Hospital Colorado
-
Contact:
- Kyle Phillips
- Phone Number: 702-777-0524
- Email: kyle.phillips@childrenscolorado.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
child over 4 months of age social, behavioral, physical, or other handicap unable to complete age-appropriate vision screening
Exclusion Criteria:
glaucoma post intraocular surgery microphthalmia other serious eye disorder inability to complete SPOT screener
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the SPOT will be effective in screening for amblyogenic risk factors
Time Frame: 12 months
|
the Spot has a sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) necessary to appropriately perform visual triage in developmentally delayed children
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 16-1911 SPOT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vision Disorders
-
NCT06602102CompletedLow Vision | Low Vision Aids | Low Vision Blindness | Low Vision Digital Assistance
-
NCT04919837RecruitingArtificial Intelligence | Ophthalmology | Low Vision Aids
-
NCT06407336Active, not recruiting
-
NCT05917457Completed
-
NCT05184036Active, not recruitingLow Vision Digital Assistance
-
NCT05647694SuspendedBlindness and Low Vision
-
NCT06477809Recruiting
-
NCT04974307TerminatedCLN3-related Disorders | Non-CLN3 Related Low Vision
-
NCT05956730Completed
Clinical Trials on Welch-Allyn Spot Vision Screener
-
NCT03147534WithdrawnHealthy | Febrile Illness
-
NCT03860727Completed
-
NCT03589716Completed
-
NCT04489407UnknownVascular Diseases | Coronavirus | Respiratory Disease | Cardiac Disease
-
NCT03998098Completed
-
NCT04968080Completed
-
NCT02475577Unknown
-
NCT01794611CompletedFailed or Difficult Intubation
-
NCT05726760Recruiting